Search for BPC-157 and you will find a confident sentence repeated across a hundred vendor sites: the courts forced the FDA to back down. It is the closest thing this market has to a legal argument, and it is doing an enormous amount of work — it is why product is moving, why clinics have put it back on the menu, and why nobody is asking the obvious follow-up question.
Which court, and what did it actually decide?
The answer is that no court has decided anything about BPC-157. Here is what actually happened, and what US courts have in fact done to people in this business.
The case everyone is referring to
In 2023 the FDA placed a group of peptide bulk drug substances, BPC-157 among them, into Category 2 of its 503A bulks list review — the bin for substances the agency considers to raise significant safety risks. Category 2 placement closed the compounding door.
Evexias Medical Centers and Farmakeio Outsourcing sued the FDA in federal court over those additions. The core complaint was procedural rather than scientific: that the agency had not substantiated the safety risks it asserted and had not followed proper process in reaching the categorisation.
The case settled in 2024. It did not go to judgment.
What a settlement is, and what it is not
This distinction is the whole article, so it is worth being blunt about it.
Under the settlement, the FDA agreed to convene its Pharmacy Compounding Advisory Committee to review several of the substances — meetings followed in late 2024 — and to follow proper notice and rulemaking process, including PCAC review, before categorising an active pharmaceutical ingredient.
What the settlement did not do:
- It did not find BPC-157 safe.
- It did not find BPC-157 lawful to compound, sell, or administer.
- It did not create any right to market it.
- It did not bind any future FDA determination on the merits.
- It produced no judicial opinion at all — nothing a later court is required to follow.
The plaintiffs won process. That is a real win, and it is a narrow one. A company that agrees to hold a meeting has not conceded that your product is legal.
What happened next, and why it is also not a green light
On 15 April 2026 the FDA announced it would remove twelve peptide bulk drug substances from Category 2, and remove GHK-Cu from Category 1. The stated reason matters and is almost universally omitted from the marketing: the removals followed nominators withdrawing their nominations. This was an administrative consequence of substances leaving the review queue — not a finding that they are safe.
Removal from Category 2 does not place a substance on the 503A bulks list, and it does not put it in Category 1. It leaves it in an unresolved middle: no longer carrying the “significant safety risks” designation, and still carrying no authorisation.
The FDA convened the PCAC on 23–24 July 2026 to consider several of them. The committee recommended most of the peptides it reviewed for the 503A bulks list and voted one down. An advisory committee recommendation is advice. The agency retains authority to accept, modify or reject it, and listing runs through rulemaking.
We track the current position in peptides and the bulks list. The editorial line there has not changed: regulatory limbo is not a green light.
What courts have actually done to people in this business
Here is the part the vendor blogs leave out. While no court has ruled on whether BPC-157 may be compounded, a federal criminal court has already sentenced conduct involving it.
In October 2020, Tailor Made Compounding — a Kentucky compounding pharmacy — and its owner entered guilty pleas in federal court. The company pleaded guilty to distributing unapproved new drugs, for conduct running from October 2018 to April 2020. It agreed to forfeit more than $1.7 million, representing its sales of the products for a single year. Its owner separately pleaded guilty to unlawfully engaging in wholesale distribution of prescription drugs without a licence, an offence carrying up to five years.
The substances in that case are a roll call of exactly what is being sold today: BPC-157, CJC-1295, ipamorelin, epitalon, semax, selank, DSIP, LL-37, PEG-MGF, melanotan II, cerebrolysin, along with several SARMs.
Note what the government did not have to prove. Not that anyone was harmed. Not that the products were contaminated or ineffective. The offence is distributing unapproved new drugs — the status of the article, not its consequences.
The other line of cases, and how it went
The compounding industry has litigated against the FDA on an adjacent front. When the agency resolved the semaglutide and tirzepatide shortages and the enforcement discretion for compounding those drugs ended, industry plaintiffs went to court to challenge the determinations.
They did not win preliminary relief. Courts deferred to the agency’s determination. The practical lesson generalises well beyond GLP-1s: challenging an FDA scientific or administrative determination in court is slow, expensive, and usually unsuccessful, and a business built on the assumption that the challenge will succeed is a business built on a coin flip. See what happened after the shortage ended.
What a court would look at if you were the defendant
If a peptide business is prosecuted or enjoined, the analysis will not be about whether BPC-157 works. It will be:
- Was the article a drug? Determined by intended use, from your labelling, website, ads, testimonials and circumstances of sale.
- Was it approved? Almost never.
- Did a compounding exemption apply? Only if the substance was eligible and every 503A or 503B condition was met.
- Was it misbranded? A prescription drug without adequate directions for lay use is misbranded independently of the approval question.
None of those four questions is answered by pointing at a settlement.
How to read peptide legal news from here
- Settlement ≠ ruling. Ask what the court held. If the answer is “it settled,” the court held nothing.
- Advisory recommendation ≠ rule. The PCAC advises; the FDA decides; rulemaking lists.
- Removal from a prohibited list ≠ addition to a permitted one. These are different lists with different consequences.
- Enforcement discretion ≠ legality. It is a statement about what the agency will pursue today, revocable tomorrow, and it binds no prosecutor.
- Ask who carried the loss. In every enforcement action to date, that has been the distributor, the pharmacy, and the practice — not the overseas supplier who assured them it was fine.
Where MDside sits
We do not build formularies on pending litigation or on advisory votes. A substance goes on the menu when there is a completed pathway for it and the supplying pharmacy can put its specific authority in writing. Until then it stays off, including when a competitor down the road is advertising it and citing a court case that did not happen.
See how our peptide programs are structured, or read the statutes underneath all of this.
Related reading
Frequently asked questions
Did a court rule that BPC-157 is legal?
No. The case usually cited settled in 2024 without a merits ruling. The settlement obliged the FDA to follow process, including advisory committee review. No court has held that BPC-157 may lawfully be compounded, sold or administered.
Did the FDA admit BPC-157 is safe when it removed it from Category 2?
No. The April 2026 removals followed nominators withdrawing their nominations. That is an administrative outcome, not a safety finding, and removal from Category 2 does not place a substance on the list you may compound from.
Has anyone actually been prosecuted over peptides?
Yes. In 2020 a compounding pharmacy pleaded guilty to distributing unapproved new drugs — BPC-157 among them — and forfeited more than $1.7 million; its owner pleaded guilty to unlicensed wholesale distribution. The FDA has also issued warning letters to peptide sellers through 2025 and 2026.
Does the government have to prove a patient was harmed?
No. Distributing an unapproved new drug is an offence based on the regulatory status of the article. Harm is relevant to sentencing and to civil exposure, not to whether the violation occurred.
If the PCAC recommended BPC-157 for the bulks list, is it now allowed?
Not on that basis alone. The committee advises the FDA; the agency may accept, modify or reject the recommendation, and adding a substance to the list runs through rulemaking. Verify the current published status before relying on it.
General information about regulatory and enforcement history, not legal advice, and not a description of any current proceeding you may be involved in. Case outcomes are summarised from public reporting; verify primary sources and consult healthcare counsel before acting.